Table of Contents
Dataset Papers in Medicine
Volume 2013 (2013), Article ID 580927, 5 pages
http://dx.doi.org/10.1155/2013/580927
Dataset Paper

Efficacy and Safety of Botulinum Toxin A for Treating Bladder Hyperactivity in Children and Adolescents with Neuropathic Bladder Secondary to Myelomeningocele

Division of Pediatric Surgery, Second University of Naples, Via S. Pansini 5, 80131 Naples, Italy

Received 4 October 2012; Accepted 6 November 2012

Academic Editors: P. Crispen, T. Efferth, P. Ferrante, and B. Weinstock-Guttman

This dataset has been dedicated to the public domain using the CC0 waiver.

Dataset http://dx.doi.org/10.1155/2013/580927/dataset

Dataset

Dataset Item 1 (Table). Demographic data of patients treated with BTX-A (leak point volume, leak point pressure, and specific capacity at 20 cm H2O are referred to baseline values and after the first injection of BTX-A). No patient presented with severe systemic complication after the injection. Thirty-eight out of forty-seven patients presented with slight hematuria for 2-3 days, 2 patients had postoperative urinary tract infection, 1 patient complained of gastric pain, treated with ranitidine, 2 patients presented with facial flushing, and 5 patients complained of mild hyposthenia of the lower limbs. All patients were hospitalized for 24 hours with catheterization and dismissed on day one. All patients experienced a significant 66.45% average increase of LPV (Wilcoxon paired rank test = 7.169 e-10) and a significant 118.57% average increase of SC 20 (Wilcoxon paired rank test = 2.466 e-12). Preoperative LPP and postoperative LPP are not significant (Wilcoxon paired rank test = 0.8858) (Table 1). At VCUG follow-up control, there were two recurrences of uinlateral grade III reflux that required a second endoscopic treatment. All patients are still on CIC regimen. With the exception of patient numbers 5, 6, 14, 18, 31, 21, and 28, which are still in clinical balance and stay dry between CICs, 22 patients received a second and 18 a third injection of BTX-A after 6–9 months for the reappearance of symptoms. After a mean follow-up of 5.7 years, 38 out of 47 patients achieved dryness between CICs, and 9 patients improved their incontinence but still need pads. Ten patients have resumed anticholinergic agents (Figures 4 and 5).

  • Column 1: Patient Number
  • Column 2: Sex
  • Column 3: Age (y)
  • Column 4: VUR
  • Column 5: Pre-LPV (mL)
  • Column 6: Post-LPV (mL)
  • Column 7: Pre-LPP (cm H2O)
  • Column 8: Post-LPP (cm H2O)
  • Column 9: Pre-SC 20 (mL)
  • Column 10: Post-SC 20 (mL)
  • Column 11: Outcome